GBT to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020

Rhea-AI Summary

Global Blood Therapeutics (GBT) will report its second quarter 2020 financial results on August 5, 2020, after U.S. markets close. A conference call will be held at 4:30 p.m. ET the same day to discuss the results. The company focuses on developing treatments for sickle cell disease and has introduced Oxbryta, the first FDA-approved therapy for the condition. GBT is also working on inclacumab to manage pain crises in sickle cell patients and is exploring new treatment avenues for SCD.

Positive

• GBT has FDA approval for Oxbryta, addressing a critical treatment gap in sickle cell disease.
• Advancements in pipeline programs, particularly inclacumab targeting pain crises.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, after U.S. financial markets close.

Management will host a conference call on Wednesday, August 5, 2020, at 4:30 p.m. ET to provide a general business update and to discuss second quarter 2020 financial results. To participate in the conference call, please dial 877-407-3982 (domestic) or 201-493-6780 (international). A live audio webcast of the conference call can be accessed on GBT’s website at www.gbt.com under the Investors section. An archived audio webcast will be available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news. 

Contact Information:           
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Stephanie Yao (investors)
650-741-7730
syao@gbt.com

 

FAQ

When will Global Blood Therapeutics report its financial results?

Global Blood Therapeutics will report its financial results on August 5, 2020.

What time is the GBT conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on August 5, 2020.

What is Oxbryta and its significance for GBT?

Oxbryta is the first FDA-approved treatment for sickle cell disease, marking a significant advancement in GBT's mission.

What is inclacumab's role in GBT's pipeline?

Inclacumab is being developed to alleviate pain crises associated with sickle cell disease.